

Note: This document has been translated from the Japanese original for reference purposes only.
 In the event of any discrepancy between this translated document and the Japanese original,
 the original shall prevail.



April 24, 2026

Company name: TECHMATRIX CORPORATION
 Representative: Takaharu Yai
 President and CEO
 (Securities code: 3762,
 Tokyo Stock Exchange Prime Market)
 Inquiries: Yoko Nakamura
 Operating Officer and Division
 Manager of Corporate Headquarters
 Telephone: +81-3(4405)7802

**(Update on Disclosed Matters) Notice Concerning The Making of Medmain Inc.
 Into a Consolidated Subsidiary Through Acquisition of Shares**

As TECHMATRIX CORPORATION (the “Company”) announced in the release “Notice Concerning Basic Agreement on Acquisition of Shares in Medmain to Make It a Consolidated Subsidiary” dated February 17, 2026 (hereinafter “February 17 announcement”), the Company and PSP Corporation (Head Office: Minato-ku, Tokyo; President: Yoshihisa Yoda; hereinafter “PSP”), a consolidated subsidiary (percentage of voting rights held: 50.02%) of the Company, have been advancing preparations ahead of the acquisition of shares in Medmain Inc. (Head Office: Fukuoka-shi, Fukuoka; CEO: Osamu Iizuka; hereinafter “Medmain”). Following on from this, the Company hereby announces that, as of today (April 24, 2026), it has reached an agreement with the shareholders of Medmain to acquire all the shares of Medmain, except for the shares held by PSP and the shares held by Mr. Osamu Iizuka, CEO of Medmain, for a total of about 2.3 billion yen. Through this acquisition, the Company intends to make Medmain one of its consolidated subsidiaries.

Accordingly, the Company also hereby announces that it has made partial amendments to the contents of the February 17 Announcement, the details of which are set out below. The amended text is underlined.

1. Number of shares held before change, number of shares to be acquired, and acquisition cost
 (Pre-amendments)

(1) Number of shares held before the change	The Company: 0 shares (Number of voting rights: 0, percentage of voting rights held: 0.00%) PSP: 5,593 shares of common stock and 17,080 shares of Class A preferred stock <u>(Number of voting rights: 22,673, percentage of voting rights held: 15.00%)</u>
(2) Number of shares to be acquired	<u>The number of shares to be acquired has not been finalized yet as the number of issued shares of Medmain will change depending on the status of exercising share options in the future. All issued shares of Medmain, except for the shares held by PSP and the shares held by Mr. Osamu Iizuka, CEO of Medmain (43,581 shares of common stock, representing 28.83% of voting rights), will be acquired.</u>
(3) Acquisition cost	<u>About 2.3 billion yen (Note)</u>

(Note) It represents the (expected) total amount of acquisition costs of the Company and PSP. The number of shares to be acquired by each of the Company and PSP has not been determined, and accordingly, their respective acquisition costs will be determined later.

(Post-amendments)

(1) Number of shares held before the change	The Company: 0 shares (Number of voting rights: 0, percentage of voting rights held: 0.00%) PSP: 5,593 shares of common stock and 17,080 shares of Class A preferred stock (Number of voting rights: 22,673, percentage of voting rights held: 15.00%)
(2) Number of shares to be acquired	<u>The Company: 8,427 shares of common stock and 14,077 shares of Class S preferred stock and 22,867 shares of Class A preferred stock</u> (Number of voting rights: 45,371, percentage of voting rights held: 29.10%) <u>PSP: 7,145 shares of common stock and 19,864 shares of Class S preferred stock and 17,295 shares of Class A preferred stock</u> (Number of voting rights: 44,304, percentage of voting rights held: 28.41%)
(3) Acquisition cost	About 2.3 billion yen (PSP: About 1.14 billion yen, The Company: About 1.16 billion yen)
(4) Number of shares held after the change	<u>The Company: 8,427 shares of common stock and 14,077 shares of Class S preferred stock and 22,867 shares of Class A preferred stock</u> (Number of voting rights: 45,371, percentage of voting rights held: 29.10%) <u>PSP: 12,738 shares of common stock and 19,864 shares of Class S preferred stock and 34,375 shares of Class A preferred stock</u> (Number of voting rights: 66,977, percentage of voting rights held: 42.95%)

2. Schedule

(Pre-amendments)

Date of conclusion of the basic agreement	Tuesday, February 17, 2026
<u>Expected date of conclusion of the share transfer agreement</u>	<u>Wednesday, April 1, 2026</u>
Expected date of implementation of the share transfer (effective date)	<u>By the end of April 2026</u>

(Post-amendments)

Date of conclusion of the basic agreement	Tuesday, February 17, 2026
<u>Date of agreement for share transfer (Note)</u>	<u>Friday, April 24, 2026</u>
Expected date of implementation of the share transfer (effective date)	<u>Thursday, April 30, 2026 (Note)</u>

(Note) An agreement pertaining to the share transfer has been reached, but the date of implementation of the share transfer will be different for each shareholder.